You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Sodium dependent glucose transporter-2 inhibitor (SGLT-2)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diabetes, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors Trial in Seoul (SGLT2 inhibitor, Glimepiride)

Not yet recruiting
  • Diabetes Mellitus
  • +2 more
  • Seoul, Korea, Republic of
    Yonsei University College of Medicine
Aug 1, 2023

Atrial Fibrillation Trial (Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor, Rhythm control and anticoagulation)

Not yet recruiting
  • Atrial Fibrillation
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Rhythm control and anticoagulation
  • (no location specified)
Aug 14, 2023

Healthy Volunteers Trial run by the NIDDK (Placebo, Canagliflozin)

Completed
  • Healthy Volunteers
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

Recruiting
  • Coronary Artery Disease
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Shah Alam, Selangor, Malaysia
    Institute for Clinical Research, National Institutes of Health,
Nov 9, 2023

(NIS) on Sodium-glucose Co-transporter-2 Inhibitors Use in

Not yet recruiting
  • Diabetes Mellitus, Type 2
  • Sodium/glucose cotransporter-2 inhibitors (SGLT2i)
  • (no location specified)
May 22, 2023

Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas Trial in Saint Louis (Dapagliflozin, BIOSENSE meters)

Completed
Has Results
  • Pancreas Cancer
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Dec 20, 2022

Acute Pancreatitis in Type 2 Diabetes Mellitus Treated With

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
Aug 19, 2022

Heart Failure With Reduced Ejection Fraction Trial in Chicago (SGLT2i, No SGLT2i)

Recruiting
  • Heart Failure With Reduced Ejection Fraction
  • Chicago, Illinois
    University of Chicago
Nov 11, 2022

Acute Kidney Injury, Cardiac Surgery, Sodium-Glucose Transporter 2 Inhibitor Trial in Netherlands (Dapagliflozin 10 MG Oral

Not yet recruiting
  • Acute Kidney Injury
  • +2 more
  • Dapagliflozin 10 MG Oral Tablet [Farxiga]
  • Placebo
  • Amsterdam, Netherlands
  • +5 more
Oct 18, 2022

Metabolic Associated Fatty Liver Disease Trial (dapagliflozin (Forxiga))

Not yet recruiting
  • Metabolic Associated Fatty Liver Disease
  • dapagliflozin (Forxiga)
  • (no location specified)
Mar 13, 2023

Cystinuria Trial in San Francisco (Dapagliflozin)

Not yet recruiting
  • Cystinuria
  • San Francisco, California
    University of California, San Francisco
Sep 13, 2022

Heart Attack, Enlarged Heart Trial in Minneapolis (Dapagliflozin, Placebo)

Recruiting
  • Heart Attack
  • Enlarged Heart
  • Minneapolis, Minnesota
    Minneapolis Heart Institute Foundation
Aug 4, 2022

SGLT2 Inhibition in Heart Failure

Recruiting
  • Heart Failure
  • Sodium-glucose cotransporter 2 inhibitor
  • Belfast, United Kingdom
    Belfast Health and Social Care Trust
Nov 15, 2023

SGLT2-I Use in DFUD: a Delphi Study

Not yet recruiting
  • Diabetic Foot Ulcer
  • eDelphi method
  • (no location specified)
Aug 14, 2023

Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan

Recruiting
  • Heart Failure
  • +2 more
  • SGLT2 inhibitor
  • Roma, RM, Italy
    Fondazione Policlinico Universitario A. Gemelli IRCSS
Jun 28, 2023

Acute Decompensated Heart Failure Trial in Chicago (SGLT2i, No SGLT2i)

Not yet recruiting
  • Acute Decompensated Heart Failure
  • Chicago, Illinois
    University of Chicago
Jun 10, 2022

SGLT-2 Inhibitors in the Treatment of Ascites

Recruiting
  • Ascites Hepatic
  • +2 more
  • SGLT2 inhibitor
  • Palermo, Italy
  • +1 more
Aug 11, 2023

MDD Trial in New York (Empagliflozin)

Not yet recruiting
  • Major Depressive Disorder
  • New York, New York
    NYU Langone Health
Feb 24, 2023

Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular

Not yet recruiting
  • SGLT2 Inhibitiors Remodeling Effect
  • Chronic Heart Disease
  • Sodium-glucose cotransporter 2 inhibitor
  • (no location specified)
Nov 14, 2023

Fatty Liver Disease Trial in Tainan (Canagliflozin 100mg)

Completed
  • Fatty Liver Disease
  • Canagliflozin 100mg
  • Tainan, Taiwan
    National Cheng Kung University Hospital
Feb 28, 2023

Chronic Kidney Diseases, Diabetes, PreDiabetes Trial in Vienna (Therapeutic carbohydrate restriction combined with an

Recruiting
  • Chronic Kidney Diseases
  • +3 more
  • Therapeutic carbohydrate restriction combined with an SGLT-2-Inhibitor
  • Vienna, Austria
    6th Medical Department with Nephrology and Dialysis, Clinik Otta
Oct 16, 2023

The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Recruiting
  • Metabolic Disease
  • Diabetes
  • SGLT-2 inhibitors
  • Samsun, İlkadım, Turkey
    Samsun Education and Research Hospital
Jun 14, 2023

Aortic Valve Stenosis Trial in Strasbourg (Myocardium biopsy)

Not yet recruiting
  • Aortic Valve Stenosis
  • Myocardium biopsy
  • Strasbourg, France
    Hôpitaux Universitaires de Strasbourg
Apr 13, 2023

SGLT-2 Inhibitors in T2DM and Moderate to Severe Liver Fibrosis

Completed
  • Type2diabetes
    • New Delhi, Delhi, India
      Fortis CDOC Hospital
    Jul 14, 2023

    Heart Failure With Reduced Ejection Fraction Trial in Porto (Sacubitril-valsartan, SGLT2 inhibitor)

    Recruiting
    • Heart Failure With Reduced Ejection Fraction
    • Porto, Portugal
    • +3 more
    Aug 9, 2023